This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zurbano, M. J. Articles by Escolar, G. Search for Related Content PubMed PubMed Citation Articles by Zurbano, M. J. Articles by Escolar, G. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CAPTOPRIL Medline Plus Health Information Heart Attack

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:1791.)
© 1999 American Heart Association, Inc.

Thrombosis

Captopril Administration Reduces Thrombus Formation and Surface Expression of Platelet Glycoprotein IIb/IIIa in Early Postmyocardial Infarction Stage

María J. Zurbano; Ignasi Anguera; Magda Heras; Eulàlia Roig; Miguel Lozano; Ginés Sanz; Ginés Escolar

From the Servicio de Hemoterapia y Hemostasia (M.J.Z., M.L., G.E.) and the Institut de Malalties Cardiovasculars (I.A., M.H., E.R., G.S.), IDIBAPS (Institut d’Investigacions Biomèdiques August Pi i Sunyer), Hospital Clínic de Barcelona, Barcelona, Spain.

Correspondence to María J. Zurbano, Hospital Clínic de Barcelona, Servicio Hemoterapia y Hemostasia, C/Villarroel, 170, 08036 Barcelona, Spain. E-mail mzurbano{at}medicina.ub.es

Abstract—Long-term administration of the angiotensin-converting enzyme inhibitor captopril in survivors of myocardial infarction (MI) reduces the risk of cardiovascular death, recurrence of MI, and unstable angina, suggesting that captopril may posses antithrombotic properties that have not been clearly elucidated. We assessed the short-term antithrombotic effects of captopril on platelet aggregation, platelet-subendothelium interaction, and the expression of major glycoproteins on platelet surface. A double-blind study was carried out in 25 patients with MI. Blood samples were taken before (baseline) and 12 days after treatment in both the control and captopril groups. Platelet aggregation was tested by conventional aggregometry using common activating agents. Platelet interaction with deeply damaged subendothelial surface was evaluated in a perfusion model, with blood maintained under flow conditions. Deposition of platelets was quantified by using computer-assisted morphometric techniques on histological sections, and it was expressed as a percentage of total vessel surface covered by platelets (CS) and as a ratio between large aggregates (T) and surface covered by platelets (100xT/CS). Glycoprotein expression was measured using flow cytometric techniques. Aggregometric responses showed no significant variations; however, in the captopril group, 100xT/CS decreased after 12 days of treatment (100xT/CS: 36±12.1% captopril versus 64±8.0% baseline; P=0.05). This parameter was also significantly decreased from that found in control group patients (100xT/CS: 67±4.5%; P=0.008). Flow cytometry showed a 30% reduction in glycoprotein IIb/IIIa expression (P=0.02). Captopril reduced the formation of large aggregates in a perfusion system, which might be related to a down-regulation of glycoprotein IIb/IIIa complex on the platelet surface. These results suggest that captopril exerts an antiplatelet effect that may contribute to its beneficial action in MI.

Key Words: captopril • platelets • vessel wall • flow cytometry

This article has been cited by other articles:

				I. Chung and G. Y.H. Lip Platelets and heart failure Eur. Heart J., November 2, 2006; 27(22): 2623 - 2631. [Abstract] [Full Text] [PDF]

				G. Mello, E. Parretti, F. Gensini, E. Sticchi, F. Mecacci, G. Scarselli, M. Genuardi, R. Abbate, and C. Fatini Maternal-Fetal Flow, Negative Events, and Preeclampsia: Role of ACE I/D Polymorphism Hypertension, April 1, 2003; 41(4): 932 - 937. [Abstract] [Full Text] [PDF]